The tariff classification of rapid diagnostic test kits from China
No Headquarters ruling in this index revokes or modifies this ruling. That is not confirmation that it is still in effect: this index does not hold every Headquarters ruling. Confirm its current status with CBP before relying on it (ruling on CBP CROSS). Text last read from CBP on Nov 21, 2026.
Ruling text
In your letter dated August 12, 2026, you requested a tariff classification ruling. Additional information was provided via email dated August 20 and August 24, 2026. The items under consideration are the iHealth Flu A&B/COVID-19/RSV Rapid Test (4-in-1), CVS™ COVID-19 & Flu A/B & RSV Antigen Test (4-in-1), iHealth COVID-19/Flu A&B Rapid Test (3-in-1), and iHealth COVID-19 Antigen Rapid Test.
These products are immunological diagnostic tests intended for the qualitative detection of specific viral antigens in human respiratory specimens. Based on the documents and email provided, each retail box contains either 1, 2, 4, 5 or 25 tests, depending on the specific product. Each test includes the necessary testing materials: a test card sealed in a pouch, a tube containing extraction solution, and a swab.
The test card is a lateral flow immunoassay device used for the qualitative detection, and where applicable differentiation, of viral antigens associated with COVID-19, influenza A, influenza B, and/or RSV (respiratory syncytial virus), depending on the specific product.
The test card generally consists of a plastic housing, sample pad, nitrocellulose membrane, absorbent pad, and antibody mix including immobilized antibodies and antibodies conjugated to detection particles such as colloidal gold or latex microspheres. Each card includes a sample well and one or more result windows with control and test lines corresponding to the analytes covered by the specific product, such as COVID-19, Flu A, Flu B, and RSV.
You explain that the essential active components of these products are biologically derived monoclonal antibodies and antibody conjugates incorporated into the test system. The monoclonal antibodies and antibody conjugates are produced through biological and biotechnological processes. They possess specific immunological binding activity against corresponding viral antigens, including SARS-CoV-2, influenza A virus, influenza B virus, and RSV, depending on the specific product configuration.
When a respiratory specimen is applied to the test component, target viral antigens in the specimen are recognized and bound by labeled monoclonal antibodies with high specificity. Through the specific interaction between viral antigens and antibodies, antigen-antibody immune complexes are formed and migrate through the membrane. These immune complexes are captured by immobilized antibodies on the test membrane, generating a visible signal for qualitative detection of the target viral antigens.
In your letter, you suggest classification in subheading 3002.15.00, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Immunological products, put up in measured doses or in forms or packings for retail sale.” We disagree. Pursuant to Chapter 30 Note 1(ij), diagnostic reagents of heading 3822 are excluded.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N364257).